Advances in biomarkers of resistance to KRAS mutation-targeted inhibitors
Abstract KRAS mutations represent the most common driver genetic alterations in multiple malignant tumors, particularly exerting well-defined oncogenic driver roles in non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. The recent success of KRAS G12C mutation-specif...
Salvato in:
| Autori principali: | , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Springer
2025-10-01
|
| Serie: | Discover Oncology |
| Soggetti: | |
| Accesso online: | https://doi.org/10.1007/s12672-025-03569-x |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|